A novel insulin formulation with a more rapid onset of action

• DOI: 10.1007/s00125-008-1095-8
• Publication Date: 2008-07-18T07:56:54Z
• Authors: S. Steiner; M. Hompesch; R. Pohl; P. Simms; F. Flacke; T. Mohr; A. Pfützner; L. Heinemann
• Keywords: Insulin lispro; Regular insulin; Crossover study; Onset of action; Insulin analog

This study evaluates the pharmacodynamic and pharmacokinetic properties of novel ultra-fast insulin product VIAject, a formulation human soluble generally recognised as safe ingredients designed to increase rate absorption.We performed five euglycaemic glucose clamps (Biostator; target blood 5 mmol/l) in ten healthy volunteers. Using crossover design with fixed treatment order, 12 IU insulin, U lispro were injected s.c. abdominal region on three days. On other two days, 6 3 injected.Subcutaneous injection resulted time-action profile characterised by an even more rapid onset action maximal metabolic activity than lispro: time early half-maximal was 33 +/- 17 min (mean SD) vs 51 13 66 15 (p < 0.05 insulin<insulin lispro<human insulin); 136 56 152 30 193 57 insulin). The first 2 h after higher (AUC infusion [GIR] 0-120 min: 915 301 781 174 580 164 mg/kg; p 0.05). A clear dose-response relationship observed doses insulin: AUCGIR 718 255 524 262 mg/kg data confirmed results.This shows that VIAject is faster lispro.